88457-23-2

Upstream product

• 67-56-1 methanol 
• 148-82-3 L-PAM 
• 265645-66-7 (S)-3-{4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-2-[3-methyl-3-(2,4,5-trimethyl-3,6-dioxo-cyclohexa-1,4-dienyl)-butyrylamino]-propionic acid methyl ester 
• 265645-64-5 (S)-3-{4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-2-[3-(5-bromo-2,4-dimethyl-3,6-dioxo-cyclohexa-1,4-dienyl)-3-methyl-butyrylamino]-propionic acid methyl ester 
• 265645-65-6 (S)-3-{4-[Bis-(2-chloro-ethyl)-amino]-phenyl}-2-[3-(2,4-dimethyl-3,6-dioxo-cyclohexa-1,4-dienyl)-3-methyl-butyrylamino]-propionic acid methyl ester 

Relevant academic research and scientific papers

Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity

Chromone has emerged as one of the most important synthetic scaffolds for antitumor activity, which promotes the development of candidate drugs with better activity. In this study, a series of nitrogen mustard derivatives of chromone were designed and syn

Selenium-containing melphalan derivative as well as preparation method and application thereof

The invention belongs to the technical field of biological pharmacy, and particularly relates to a selenium-containing melphalan derivative as well as a preparation method and application thereof. Selenium element is introduced into a melphalan structure, the selenium-containing melphalan derivative with a novel structure is synthesized, and the compound has antitumor activity and can be used for anti-cancer drugs.

Design and synthesis of β-carboline derivatives with nitrogen mustard moieties against breast cancer

To discover the promising antitumor agents, a series of β-carboline derivatives with nitrogen mustard moieties were designed and synthesized. Most target derivatives showed antiproliferative activity against MCF-7 and MDA-MB-231 cells. Among them, (1-meth

Mechlorethamine quinolone derivative and preparing method and application thereof

The invention relates to a mechlorethamine quinolone derivative (I). A preparing method of the derivative comprises the steps of firstly, conducting reduction and formylation on a quinolone compound to prepare 3-formyl quinolone (IV), and then carrying ou

Novel enmein-type diterpenoid hybrids coupled with nitrogen mustards: Synthesis of promising candidates for anticancer therapeutics

Natural derived enmein-type diterpenoids exert cytotoxicity against a wide range of human cancer cells. Yet their medicinal applications are hindered by insufficient potency for chemotherapy. Hence, a series of novel enmein-type diterpenoid hybrids coupled with nitrogen mustards were designed and synthesized to increase antitumor efficacy while reducing systemic toxicity. Most conjugates exhibited stronger antiproliferative activities than parent diterpenoids and nitrogen mustards, especially for multidrug-resistant tumor cell line Bel-7402/5-FU. Among them, compound E2 showed the most potent inhibitory activities in human leukemia HL-60 cells, human prostate cancer PC-3 cells, human liver cancer Bel-7402 cells and drug-resistant human liver cancer Bel-7402/5-FU cells with IC50 values of 7.83 μM, 3.97 μM, 0.77 μM and 2.07 μM, respectively. Additionally, high selectivity with selectivity index over 130 was also observed from cytotoxic evaluation between L-02 human normal liver cells and Bel-7402 malignant liver cells. Further studies on mechanism of action indicated that E2 induced both apoptosis and G1 phase cell cycle arrest in Bel-7402 hepatoma cells. Moreover, the dysfunction in mitochondrial pathway was also involved in E2 initiated apoptotic activation, which entailed the loss of mitochondrial membrane potential followed by upregulating the bax/bcl-2 ratio and increasing the expression of cytochrome c, p53, caspase-3 and -9. Overall, E2 has the potential to emerge as a promising drug candidate for cancer therapy.

Novel hybrids of brefeldin A and nitrogen mustards with improved antiproliferative selectivity: Design, synthesis and antitumor biological evaluation

A series of novel conjugates of brefeldin A (11a?c, 12a?c and 13a?c) were obtained by introducing a variety of nitrogen mustards at 4-OH or 7-OH position to explore more efficacious and less toxic antitumor agents. The antiproliferative activities were te

Design and synthesis of novel nitrogen mustard-evodiamine hybrids with selective antiproliferative activity

A series of novel nitrogen mustard-evodiamine hybrids were synthesized and evaluated for their antitproliferative properties. The antiproliferative activities of 10a–d, 11a–d, and 12a–d against four different kinds of human cancer cell lines (PC-3, HepG2, THP-1 and HL-60) and human normal peripheral blood mononuclear cells (PBMC) were determined. The results showed that all the target hybrid compounds exhibited antiproliferative activities against tested human tumor cell lines to some extent and no antiproliferative activities (>200 μM) against human normal PBMC cells. The antiproliferative selectivity between tumorous and normal cells was very useful for further antitumor drug development. Among the target compounds, 12c showed the strongest cytotoxicity against two tumor cell lines (THP-1 and HL-60) with IC50 values of 4.05 μM and 0.50 μM, respectively, and selected for further mechanism study in HL-60 cells. The results showed that 12c could induce HL-60 cells apoptosis and arrest at G2 phase at low sub-micromolar concentrations via mitochondria-related pathways.

Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates

A series of novel hybrids from natural product oridonin and nitrogen mustards were designed and synthesized to obtain more efficacious and less toxic antitumor agents. The antiproliferative evaluation showed that most conjugates were more potent than their parent compounds oridonin and clinically used nitrogen mustards against four human cancer cell lines (K562, MCF-7, Bel-7402, and MGC-803). Furthermore, the representative compounds 16a-c exhibited antiproliferative activities against the multidrug resistant cell lines (SW620/AD300 and NCI-H460/MX20). It was shown that the most effective compound 16b possesses a strong inhibitory activity with an IC50 value 21-fold lower than that of oridonin in MCF-7 cells and also exhibits selective cytotoxicity toward the cancer cells. Intriguingly, compound 16b has been demonstrated to significantly induce apoptosis and affect cell cycle progression in human hepatoma Bel-7402 cells.

MELPHALAN PRODRUGS

Shown and described are the synthesis of more potent forms of C-Mel, a prodrug used in Antibody-Directed Enzyme Prodrug Therapy, that releases the clinically used anticancer alkylating agent melphalan extracellularly. Shown and described are the synthesis

Reductive and Bioreductive Activation is Controlled by Electronic Properties of Substituents in Conformationally-Constrained Anticancer Drug Delivery Systems

Conformationally-constrained, anticancer drug delivery systems (TDDS) containing the methyl ester of melphalan (as a model drug) were synthesized using electron-withdrawing or electron-donating functional groups to modulate reductive and bioreductive activation. The electronic nature of substituents in TDDS was found to control reductive and bioreductive activation of TDDS, thus influencing drug delivery from TDDS.